Shukra Pharmaceuticals Quarterly Results

Latest Quarter Net Profit
₹13 Cr
QSept 2026
Quarterly Results

Shukra Pharmaceuticals quarterly results. In Sept 2026, Shukra Pharmaceuticals (SHUKRAPHAR) reported revenue ₹45 Cr and net profit ₹13 Cr — revenue +462.5% YoY. View SHUKRAPHAR yearly price range for the annual high/low range and current price position.

SHUKRAPHAR Quarterly Results — Revenue, Profit & EPS Highlights

Shukra Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore Shukra Pharmaceuticals share price performance to track price trends across different timeframes.

  • Revenue of ₹45 Cr in Sept 2026 (+542.9% vs Mar 2026, +462.5% vs Sept 2025)
  • Net Profit of ₹13 Cr in Sept 2026 (+750.0% vs Mar 2026, +550.0% vs Sept 2025)
  • EBITDA of ₹19 Cr in Sept 2026 (+850.0% vs Mar 2026)
  • Operating Margin of 42.0% in Sept 2026 (+31.0pp vs Mar 2026)
  • Earnings Per Share of ₹0.29 in Sept 2026 (+825.0% vs Mar 2026)

Shukra Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS

SHUKRAPHAR quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Sept 2026 Mar 2026 Jun 2026 Sept 2025 Mar 2025 QoQ YoY
Revenue (₹ Cr) 45 7 24 8 15 542.9% 462.5%
Net Profit (₹ Cr) 13 -2 13 2 5 - -
EBITDA (₹ Cr) 19 2 20 1 9 - -
EPS (₹) 0.29 -0.04 0.30 0.05 0.12 - -
Operating Margin (%) 42.0% 11.0% 81.0% -7.0% 55.0% - -

SHUKRAPHAR Share Price Trend — 1-Year Movement Across Quarterly Results

Shukra Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit SHUKRAPHAR share price.

Profitability Ratios

Profit Margin 28.9%
EBITDA Margin 42.2%
Operating Margin 42.0%
ROE (Annual) 57.8%

Balance Sheet Highlights

Total Assets ₹117 Cr
Total Equity ₹90 Cr
Current Assets ₹ Cr
Current Liabilities ₹5 Cr

Cash Flow Analysis

Operating Cash Flow ₹3 Cr
Investing Cash Flow ₹-14 Cr
Financing Cash Flow ₹5 Cr
Net Cash Flow ₹-6 Cr

Current Market Data

Current Price ₹82.20
Exchange NSE
Last Updated Nov 18, 2026

SHUKRAPHAR vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Shukra Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Sept 2026
₹451,074.97 Cr 1900.0 16,617 1,995 +10.6% - 12.0% 228.9
Divis Laboratories
Sept 2026
₹294,139.19 Cr 11178.0 3,770 1,127 +26.3% - 29.9% 263.1
Torrent Pharmaceuti…
Mar 2026
₹188,719.51 Cr 4611.0 4,111 364 +27.7% +42.2% 8.9% 400.6
Apollo Hospitals
Sept 2026
₹126,832.45 Cr 8738.0 7,673 660 +15.2% - 8.6% 199.4
Laurus Labs
Sept 2026
₹125,946.78 Cr 2306.0 2,219 436 +21.7% - 19.6% 282.3
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data

QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores